TFE3 and nonpapillary renal cell carcinoma: However, TFE3-rearranged-RCC exhibited a higher recurrence rate than ccRCC (50% vs. 18%; p = 0.04), in spite of a significantly longer follow-up for ccRCC (71.4 months vs. 27.8 months; p = 0.001).